RICHLAND, WA--(Marketwire - October 29, 2012) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 28-31, 2012 in Boston, Massachusetts at the Boston Convention and Exhibition Center. According to IsoRay CEO Dwight Babcock, "The medical community is clearly becoming aware of the innovative alternatives that our products offer as an important advance over previous brain and lung cancer treatments."
IsoRay's Cesium-131 sutured seeds stranded mesh and the GliaSite® radiation therapy system gives physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain and lung tissue compared to other alternative treatments. IsoRay's cancer fighting products diminishes the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.
Babcock says adding additional sales representatives as well as presenting our products at new venues has created increased inquiries from the medical community about IsoRay's Cesium-131 (Cs-131) seed sutured mesh for the treatment of a wide array of cancers throughout the body including brain and lung cancers. With six (6) papers being presented at ASTRO, we are encouraged as all of them showed exceptional results realized in metastasized brain cancers, lung cancer and prostate cancer. Babcock says medical thought leaders recognize the important need for this new powerful weapon in the battle against cancer and Cecium-131 is that solution."
IsoRay has participated over the last quarter in the following new industry shows expanding its product awareness to differing specialists while sharing the benefits of Cesium-131 in their efforts to fight cancer.
1. Chicago Multidisciplinary Symposium in Thoracic Oncology (CMS)
2. Harvard Medical School 8th Annual Brachytherapy Review
3. Congress of Neuroncological Surgeons Annual Meeting (CNS)
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite® radiation therapy system.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of the Gliasite delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSite® or Cesium-131 internationally will increase or continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, patient results achieved with Cesium-131 or the Gliasite® delivery system, successful completion of future research and development activities, our ability to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.